Valuation : Lantheus Holdings, Inc.

Market Cap 6.59B 5.67B 5.33B 4.87B 9.1B 623B 9.13B 63.21B 24.43B 319B 24.75B 24.21B 1,017B P/E 2026 *
21.4x
P/E 2027 * 18.1x
Enterprise Value 6.37B 5.48B 5.15B 4.7B 8.8B 603B 8.83B 61.11B 23.62B 309B 23.93B 23.41B 983B EV / Sales 2026 *
4.25x
EV / Sales 2027 * 3.62x
Free-Float
88.15%
Yield 2026 *
-
Yield 2027 * -
1 day-0.01%
1 week+0.01%
Current month+0.01%
1 month+0.02%
3 months-0.01%
6 months+39.15%
Current year+51.72%
1 week 100.54
Extreme 100.5372
101
1 month 99.97
Extreme 99.97
101.43
Current year 63.37
Extreme 63.37
111.86
1 year 49.67
Extreme 49.67
111.86
3 years 47.25
Extreme 47.25
126.89
5 years 22.2
Extreme 22.2
126.89
10 years 7.18
Extreme 7.18
126.89
Manager TitleAgeSince
Chief Executive Officer 66 2025-12-31
Director of Finance/CFO 60 2018-09-20
Chief Tech/Sci/R&D Officer 64 2025-07-31
Director TitleAgeSince
Director/Board Member 80 2012-04-30
Chairman 66 2024-02-29
Director/Board Member 61 2016-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
8/31/26 Tax

Chief Financial Officer

-721 0.0011%
8/17/26 Tax

Controller/Auditor

-463 0.0007%
8/17/26 Tax

Chief Technology Officer

-2,536 0.0039%
Change 5-day change 1-year change 3-year change Capi.($)
-0.01%+0.01%+84.42%+52.61% 6.59B
+0.23%+1.50%+168.44%+357.51% 21.66B
-2.29%-3.33%-38.67%-21.69% 10.16B
-0.90%+0.32%+348.78%+24.85% 8.16B
-0.99%-1.65%-28.06% - 7.08B
-1.11%-2.36%-21.62%-13.93% 6.03B
0.00%-3.37%-10.08%-20.68% 4.33B
+2.96%+2.56%+80.17%+92.05% 4.22B
-1.43%-1.69%-19.83%-30.01% 2.81B
-2.87%+2.96% - - 1.39B
Average -0.64%+0.01%+62.62%+55.09% 7.24B
Weighted average by Cap. -0.48%-0.45%+92.46%+128.27%

Financials

2026 *2027 *
Net sales 1.5B 1.29B 1.21B 1.11B 2.07B 142B 2.08B 14.38B 5.56B 72.62B 5.63B 5.51B 231B 1.65B 1.42B 1.34B 1.22B 2.28B 156B 2.29B 15.86B 6.13B 80.09B 6.21B 6.07B 255B
Net income 320M 275M 258M 236M 441M 30.22B 443M 3.06B 1.18B 15.48B 1.2B 1.17B 49.29B 392M 337M 317M 290M 542M 37.1B 543M 3.76B 1.45B 19B 1.47B 1.44B 60.52B
Net Debt -219M -188M -177M -161M -302M -20.67B -303M -2.1B -810M -10.59B -821M -803M -33.72B -598M -514M -483M -441M -825M -56.53B -828M -5.73B -2.22B -28.95B -2.24B -2.2B -92.21B
Logo Lantheus Holdings, Inc.
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company, dedicated to helping clinicians find, fight, and follow disease to deliver better patient outcomes. Its product categories include oncology, neurology, cardiology, and strategic partnerships and others. Its products include PYLARIFY, Neuraceq, and DEFINITY. PYLARIFY TruVu is indicated for PET imaging of PSMA-positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy, or suspected recurrence based on elevated serum prostate-specific antigen (PSA). Neuraceq is an Alzheimer's disease radiodiagnostic. Its commercial products are used by cardiologists, internists, neurologists, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists across a range of clinical care settings. Its diagnostic products provide information that enables healthcare professionals (HCPs) to better detect, characterize, or rule out diseases.
Employees
1,193
Date Price Change Volume
26-09-04 US$100.97 -0.01% 859,896
26-09-03 US$100.98 +0.17% 737,070
26-09-02 US$100.81 -0.07% 780,327
26-09-01 US$100.88 -0.08% 1,380,180
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
100.97USD
Average target price
107.74USD
Spread / Average Target
+6.70%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LNTH Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!